Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score

To determine the influence of maximal androgen blockade (MAB) and non-MAB hormonal therapy with an luteinizing hormone releasing hormone (LHRH) analog on overall survival of prostate cancer patients in the Japan Study Group of Prostate Cancer (J-CaP) registry according to risk, as assessed using the...

Full description

Bibliographic Details
Main Author: Hideyuki Akaza
Format: Article
Language:English
Published: Elsevier 2013-06-01
Series:Prostate International
Subjects:
Prostate neoplasms
Maximal androgen blockade
Overall survival
Primary androgen deprivation therapy
Risk scoring
Online Access:http://www.sciencedirect.com/science/article/pii/S2287888215300295

Internet

http://www.sciencedirect.com/science/article/pii/S2287888215300295

Similar Items